title: Dynamic cardiomyoplasty: clinical follow-up at 12 years.
abstract: OBJECTIVE
  The purpose of this study is to evaluate the long-term outcome of dynamic cardiomyoplasty. This surgical technique was conceived to assist the failing heart. The many proposed mechanisms of action of cardiomyoplasty are: (1) systolic assist; (2) limitation of ventricular dilation; (3) reduction of ventricular wall stress (sparing effect); (4) ventricular remodeling with an active girdling effect; (5) angiogenesis; and (6) a neurohumoral effect.
  
  
  METHODS
  We investigated 95 patients in our hospital undergoing this procedure due to severe chronic heart failure, refractory to optimal medical treatment. Patients had a mean age of 51 +/- 12 years. The etiology of heart failure was ischemic 55%, idiopathic 34%, ventricular tumor 6%, and other 5%. The mean follow-up was 44 months.
  
  
  RESULTS
  The mean New York Heart Association (NYHA) functional class improved postoperatively from 3.2 to 1.8. Average radioisotopic left ventricular (LV) ejection fraction increased from 17 +/- 5 to 27 +/- 4% (P < 0.05). Stroke volume index increased from 32 +/- 7 to 43 +/- 8 ml/beat per m2 (P < 0.05). The heart size remained stable over the long term. Following cardiomyoplasty, the number of hospitalizations due to congestive heart failure was reduced to 0.4 hospitalizations/patient per year (preoperative: 2.5, P < 0.05). Computed tomography scans showed at long term a preserved latissimus dorsi muscle structure in 84% of patients. Survival probability at 7 years is 54%. Six patients underwent heart transplant after cardiomyoplasty (mean delay: 25 months), due to the natural evolution of their underlying heart disease. There were no specific technical difficulties.
  
  
  CONCLUSIONS
  Clinically, this procedure reverses heart failure, improves functional class and ameliorates quality of life. The latissimus dorsi muscle histological structure is maintained at long-term, when postoperative electrostimulation is performed, avoiding excessive stimulation. Cardiomyoplasty may delay or prevent the progression of heart failure and the indication of cardiac transplantation.
authors.affiliation: Department of Cardiovascular Surgery, Broussais Hospital, Paris, France.
authors.forename: J C
authors.initials: JC
authors.lastname: Chachques
authors.forename: J P
authors.initials: JP
authors.lastname: Marino
authors.forename: P
authors.initials: P
authors.lastname: Lajos
authors.forename: R
authors.initials: R
authors.lastname: Zegdi
authors.forename: N
authors.initials: N
authors.lastname: D'Attellis
authors.forename: P
authors.initials: P
authors.lastname: Fornes
authors.forename: J N
authors.initials: JN
authors.lastname: Fabiani
authors.forename: A
authors.initials: A
authors.lastname: Carpentier
mesh_terms: D000206:Actuarial Analysis; D018421:Cardiomyoplasty / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000401:mortality / Q000601:surgery*; D016027:Heart Transplantation / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome